Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more
Market Cap & Net Worth: Biovica International AB (publ) (BIOVIC-B)
Biovica International AB (publ) (ST:BIOVIC-B) has a market capitalization of $8.56 Million (Skr96.08 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #33533 globally and #523 in its home market, demonstrating a 19.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biovica International AB (publ)'s stock price Skr0.35 by its total outstanding shares 275289064 (275.29 Million).
Biovica International AB (publ) Market Cap History: 2017 to 2026
Biovica International AB (publ)'s market capitalization history from 2017 to 2026. Data shows change from $283.43 Million to $9.82 Million (-32.55% CAGR).
Biovica International AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biovica International AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.05x
Biovica International AB (publ)'s market cap is 1.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $283.43 Million | $632.00K | -$14.86 Million | 448.47x | N/A |
| 2018 | $206.13 Million | $2.72 Million | -$18.06 Million | 75.70x | N/A |
| 2019 | $289.57 Million | $3.00 Million | -$21.56 Million | 96.36x | N/A |
| 2020 | $1.26 Billion | $1.67 Million | -$30.32 Million | 751.90x | N/A |
| 2021 | $1.02 Billion | $2.08 Million | -$39.48 Million | 489.14x | N/A |
| 2022 | $200.00 Million | $2.04 Million | -$60.00 Million | 97.80x | N/A |
| 2023 | $63.31 Million | $3.38 Million | -$110.49 Million | 18.71x | N/A |
| 2024 | $49.08 Million | $7.29 Million | -$124.82 Million | 6.73x | N/A |
| 2025 | $9.08 Million | $8.62 Million | -$87.62 Million | 1.05x | N/A |
Competitor Companies of BIOVIC-B by Market Capitalization
Companies near Biovica International AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Biovica International AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Biovica International AB (publ) Historical Marketcap From 2017 to 2026
Between 2017 and today, Biovica International AB (publ)'s market cap moved from $283.43 Million to $ 9.82 Million, with a yearly change of -32.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr9.82 Million | +8.11% |
| 2025 | Skr9.08 Million | -81.50% |
| 2024 | Skr49.08 Million | -22.48% |
| 2023 | Skr63.31 Million | -68.34% |
| 2022 | Skr200.00 Million | -80.31% |
| 2021 | Skr1.02 Billion | -19.14% |
| 2020 | Skr1.26 Billion | +333.90% |
| 2019 | Skr289.57 Million | +40.48% |
| 2018 | Skr206.13 Million | -27.27% |
| 2017 | Skr283.43 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biovica International AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.56 Million USD |
| MoneyControl | $8.56 Million USD |
| MarketWatch | $8.56 Million USD |
| marketcap.company | $8.56 Million USD |
| Reuters | $8.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.